Translated data: This article introduces the collaboration between AI-driven cancer detection startup C2i Genomics and one of Israel's top hospitals. C2i Genomics employs cloud-based artificial intelligence solutions for early cancer detection, with a focus on whole-genome minimal residual disease (MRD) detection. This partnership will propel research and clinical trials within the hospital and facilitate drug development for pharmaceutical companies.